Over the 10-year forecast period for Ovarian Cancer (OC) from 2019 to 2029, we expect:
A total market growth from $1.1billion to $2.8billion
A major shift in treatment paradigms with the adoption of a diverse range of targeted therapies in a category where the broad standard of care for most patients has been platinum-based regimens.
Rapid adoption of PARPi and PD-1/PD-L1 targeting regimens and the emergence of first in class therapies (e.g. P53 activator APR-246, GAS-6i, tisotumab vedotin, oncolytic virus ONCOS-102 and cancer vaccine-DPX-Survivac).
Targeted therapies will drive longer treatment duration to deliver better treatment outcomes (evidenced in clinical trial results), offer better value and command premium pricing.
Roche will continue to dominate the market as the single largest player with approx. 31% of total market revenue in 2029 (down from 48% in 2019). Tecentriq (atezolizumab, PD-L1) gaining approval in OC in 2021 will offset some of the impact from loss of market protection on Avastin (bevacizumab) in 2019.
Generics to increase in total market revenue share from 18% to 25% by 2029 (driven by loss of exclusivity events).
Approximately 30% of the remaining market revenue will be generated by current OC drug manufacturers AstraZeneca, Tesaro and Clovis Pharmaceuticals, with the remaining share being generated by new market entrants such as Merck, Genmab and Aprea Therapeutics.
Key Topics Covered
Classification of Ovarian Cancer
Histopathology and Therapy-Specific Disease Classification
Risk Factors & Prevention
Diagnosis of the Disease
Patient & Clinical Management Guidelines (ESMO)
Patient & Clinical Management Flow developed for the forecast using NCCN and ESMO guidelines
Treatment Landscape - Overview
Molecules used in Ovarian Cancer Therapy
Regimens in Ovarian Cancer Therapy
Share of Patients Initiating Treatment per Line of Therapy
Total Market Forecast
Market Forecast Revenue by Line of Therapy
Revenue Forecast by Patient Segments (BRCA vs Wild Type)
Patient Share Initiating Regimen per Line of Therapy